Susquehanna International Group
VTGN icon

Susquehanna International Group’s VistaGen Therapeutics VTGN Stock Holding History

Susquehanna International Group’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,000
Closed -$49.5K – 14201
2025
Q4 		$49.5K Buy
75,000
+60,500
+417% +$219K ﹤0.01% 11753
2025
Q3 		$51.5K Buy
+14,500
New +$43.3K ﹤0.01% 11850
2025
Q1 		– Sell
-91,100
Closed -$269K – 13551
2024
Q4 		$269K Sell
91,100
-300
-0.3% -$844 ﹤0.01% 10067
2024
Q3 		$275K Buy
91,400
+35,300
+63% +$120K ﹤0.01% 9793
2024
Q2 		$195K Buy
56,100
+14,600
+35% +$63.2K ﹤0.01% 10387
2024
Q1 		$219K Sell
41,500
-3,100
-7% -$14.9K ﹤0.01% 10416
2023
Q4 		$229K Sell
44,600
-20,400
-31% -$77.2K ﹤0.01% 10390
2023
Q3 		$341K Buy
+65,000
New +$289K ﹤0.01% 9086
2022
Q4 		– Sell
-687
Closed -$3K – 13795
2022
Q3 		$3K Sell
687
-2,673
-80% -$26.5K ﹤0.01% 12925
2022
Q2 		$89K Buy
3,360
+2,863
+576% +$101K ﹤0.01% 11577
2022
Q1 		$18K Sell
497
-2,683
-84% -$117K ﹤0.01% 12650
2021
Q4 		$186K Sell
3,180
-790
-20% -$51.4K ﹤0.01% 11535
2021
Q3 		$326K Buy
+3,970
New +$345K ﹤0.01% 10415

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group's VTGN Position: Q1 2026 in Review

Susquehanna International Group reduced its VistaGen Therapeutics (VTGN) stake by 57% in Q1 2026, selling an estimated $117K and leaving 142,607 shares worth $81.5K. The position accounts for ﹤0.01% of the portfolio, ranked #12453.

Susquehanna International Group first reported a position in VTGN in Q4 2017 and has held it in 25 quarters since. The position peaked at $1.53M in Q1 2024. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Susquehanna International Group held 142,607 shares of VistaGen Therapeutics worth $81.5K as of Q1 2026.
  • Susquehanna International Group sold 192,179 VistaGen Therapeutics shares in Q1 2026, an estimated $117K.
  • VistaGen Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12453 holding.
  • Susquehanna International Group first reported a position in VistaGen Therapeutics in Q4 2017 and has held it in 25 quarters since.
  • Susquehanna International Group's VistaGen Therapeutics position peaked at $1.53M in Q1 2024.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.